Representative(s):

Holly Wayne
Territory Business Manager
608.852.0739
hwayne@rigel.com

Company URL:

•  https://tavalissehcp.com/

Promotional Links:

• Patient Website: https://tavalisse.com/
• BJH Publication: tavalisse2L.com 
• TAVALISSE Resources: https://tavalissehcp.com/resource-library
• TAVALISSE Patient Onboarding Materials: https://tavalissehcp.com/start

Social Media Links:

• Facebook: https://www.facebook.com/Rigel-Pharmaceuticals
• Linkedin: https://www.linkedin.com/company/rigel/
• Twitter: https://twitter.com/RigelPharma

Rigel Pharmaceuticals is a biotechnology company dedicated to improving the lives of patients through the discovery, development, and commercialization of novel small molecule drugs. Rigel is focused on immune and hematologic disorders, cancer, and rare diseases and see great opportunity to help patients who have diseases where few to no approved treatment options exist.

Rigel's first FDA approved product TAVALISSE® (fostamatinib disodium hexahydrate) tablets was approved in 2018.

Please visit www.TAVALISSEhcp.com to see the full Prescribing Information and learn more.

Virtual Drop In

March 6th,  7:00am – 4:00pm CST.  

Click here to join the zoom meeting

Meeting ID: 988 7071 2002

Passcode: 057020